Literature DB >> 19941078

Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Helen Dakin1, Stavros Petrou, Mark Haggard, Sarah Benge, Ian Williamson.   

Abstract

PURPOSE: To investigate the statistical relationship between the OM8-30 health-related quality of life measure for children with otitis media with effusion (OME) and measures of health utility (Health Utilities Index [HUI] Mark 3 and Mark 2) and to develop models to estimate HUI3 and HUI2 health utilities from OM8-30 scores.
METHODS: A placebo-controlled, randomised trial (GNOME) evaluating intranasal mometasone in 217 children with OME provided concurrent responses to OM8-30 and HUI at three time points. Ordinary least squares (OLS), generalised linear models and two-step regression analyses were used to predict HUI3 and HUI2 utilities based on OM8-30 facet and domain scores.
RESULTS: OLS models including all nine OM8-30 facets with or without predicted hearing level (HL) produced the best predictions of HUI3 utilities (mean absolute error: 0.134 with HL and 0.132 without; R(2): 0.63 with HL and 0.596 without). An OLS model predicting HUI3 utilities based on the two OM8-30 domain scores, reported hearing difficulties, predicted HL, age and sex also produced accurate predictions.
CONCLUSION: Regression equations predicting HUI3 and HUI2 utilities based on OM8-30 facet and domain scores have been developed. These provide an empirical basis for estimating quality-adjusted life years (QALYs) for interventions in children with OME.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941078     DOI: 10.1007/s11136-009-9558-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  41 in total

1.  Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons.

Authors:  David Feeny; William Furlong; Saroj Saigal; Jian Sun
Journal:  Soc Sci Med       Date:  2004-02       Impact factor: 4.634

2.  Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample.

Authors:  Peter Franks; Erica I Lubetkin; Marthe R Gold; Daniel J Tancredi; Haomiao Jia
Journal:  Med Decis Making       Date:  2004 May-Jun       Impact factor: 2.583

3.  How appropriate is the OM6 as a discriminative instrument in children with otitis media?

Authors:  Haytham Kubba; Iain R C Swan; Stuart Gatehouse
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-06

4.  Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3.

Authors:  Cheryl L Cox; Shelly Lensing; Shesh N Rai; Pam Hinds; Elizabeth Burghen; Ching-Hon Pui
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

Review 5.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

6.  Distribution-based and anchor-based approaches provided different interpretability estimates for the Hydrocephalus Outcome Questionnaire.

Authors:  Abhaya V Kulkarni
Journal:  J Clin Epidemiol       Date:  2006-02       Impact factor: 6.437

7.  Screening for otitis media with effusion in preschool children.

Authors:  G A Zielhuis; G H Rach; P van den Broek
Journal:  Lancet       Date:  1989-02-11       Impact factor: 79.321

8.  Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.

Authors:  Alastair M Gray; Oliver Rivero-Arias; Philip M Clarke
Journal:  Med Decis Making       Date:  2006 Jan-Feb       Impact factor: 2.583

9.  A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.

Authors:  I Williamson; S Benge; S Barton; S Petrou; L Letley; N Fasey; G Abangma; H Dakin; P Little
Journal:  Health Technol Assess       Date:  2009-08       Impact factor: 4.014

10.  Self-reported health status and health-related quality of life of teenagers who were born before 29 weeks' gestational age.

Authors:  Ron Gray; Stavros Petrou; Christine Hockley; Frances Gardner
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124

View more
  18 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Authors:  Eun-ju Kim; Su-Kyoung Ko; Hye-Young Kang
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

3.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

4.  Mapping EQ-5D utility scores from the PedsQL™ generic core scales.

Authors:  Kamran A Khan; Stavros Petrou; Oliver Rivero-Arias; Stephen J Walters; Spencer E Boyle
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

5.  Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs).

Authors:  Billingsley Kaambwa; Gang Chen; Julie Ratcliffe; Angelo Iezzi; Aimee Maxwell; Jeff Richardson
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

6.  Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.

Authors:  Billingsley Kaambwa; Julie Ratcliffe
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

7.  Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications.

Authors:  John Yfantopoulos; Athanasios Chantzaras
Journal:  Eur J Health Econ       Date:  2020-03-03

8.  Effect of nasal balloon autoinflation in children with otitis media with effusion in primary care: an open randomized controlled trial.

Authors:  Ian Williamson; Jane Vennik; Anthony Harnden; Merryn Voysey; Rafael Perera; Sadie Kelly; Guiqing Yao; James Raftery; David Mant; Paul Little
Journal:  CMAJ       Date:  2015-07-27       Impact factor: 8.262

9.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

10.  Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting.

Authors:  Stavros Petrou; Alastair Gray
Journal:  BMJ       Date:  2011-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.